Mantle cell lymphoma+2
Not recruitingStudy on KTE-X19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma Responding Partially to Ibrutinib
Study on KTE-X19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma Responding Partially to Ibrutinib
- Disease:Mantle cell lymphomaMantle cell lymphoma recurrent+1
- Substances:FludarabineIbrutinib+2
Italy- Participants:18–64 years · 65+ years
- Substances:Fludarabine
- Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori














